Live Breaking News & Updates on Janssen pharmaceuticals

Stay informed with the latest breaking news from Janssen pharmaceuticals on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Janssen pharmaceuticals and stay connected to the pulse of your community

Coronary sinus reducer for the treatment of refractory angina (ORBITA-COSMIC): a randomised, placebo-controlled trial

Coronary sinus reducer for the treatment of refractory angina (ORBITA-COSMIC): a randomised, placebo-controlled trial
thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.

Basildon , Essex , United-kingdom , London , City-of , Bristol , Brompton , Medway , South-essex , Massachusetts , United-states , Boston

Addex to Present at the Swiss Biotech Day 2024

Geneva, Switzerland, April 19, 2024 - Addex Therapeutics , a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, announced today that CEO, Tim Dyer, will...

Switzerland , United-states , Geneva , Genè , American , Swiss , Mike-sinclair , Tim-dyer , Janssen-pharmaceuticals-inc , Congress-center , Swiss-exchange , Nasdaq

Addex to Present at the Swiss Biotech Day 2024

Addex to Present at the Swiss Biotech Day 2024
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Geneva , Genè , Switzerland , United-states , American , Swiss , Tim-dyer , Mike-sinclair , Janssen-pharmaceuticals-inc , Swiss-exchange , Congress-center , Nasdaq

Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18, 2024

Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18, 2024
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Geneva , Genè , Switzerland , United-states , American , Swiss , Tim-dyer , Mike-sinclair , Mikhail-kalinichev , Swiss-exchange , Janssen-pharmaceuticals-inc , Nasdaq

Outdated Diabetes Drug Retains Potential Benefits

Outdated Diabetes Drug Retains Potential Benefits
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

University-of-california-san-diego , California , United-states , Switzerland , San-diego , Swiss , Americans , Thiazolidinediones-tzds , Charlene-miciano , Rizaldyc-zapata , Jerrold-olefsky , Hong-gao

This Outdated Diabetes Drug Still Has Something to Offer

Researchers from UC San Diego have discovered the biochemical workings of an old-fashioned diabetes drug, and it's helping them develop new, safer alternatives.

University-of-california-san-diego , California , United-states , Switzerland , San-diego , Swiss , Americans , Gautam-bandyopadhyay , Hong-gao , Jerrold-olefsky , Rizaldyc-zapata , Felipe-castellani-gomes

Janssen v. Teva: Not an April Fool's Day Joke for Life Sciences Companies | Goodwin

Janssen v. Teva: Not an April Fool's Day Joke for Life Sciences Companies | Goodwin
jdsupra.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jdsupra.com Daily Mail and Mail on Sunday newspapers.

Janssen-pharmaceuticals-inc , International-publication-no , Teva-pharmaceuticals-united-states-inc , Federal-circuit , Janssen-pharmaceuticals , Pharmaceuticals-united-states , International-publication ,

Georgia to distribute $638M settlement through grant program to combat deadly opioid epidemic

The state has launched a grant program for awarding the hundreds of millions of dollars in opioid settlement funds coming to Georgia. A total of $638 million will flow into Georgia, with three-fourths of the funds being distributed through the grant process unveiled Monday. Another 25%, or $159 million, will be shared among the city […] The post Georgia to distribute $638M settlement through grant program to combat deadly opioid epidemic appeared first on Georgia Recorder.

Georgia , United-states , Catoosa-county , Atlanta , Kevin-tanner , Brian-kemp , Gary-sisk , Jeff-breedlove , Evan-meyers , Department-of-behavioral-health , Janssen-pharmaceuticals , Johnson

Adagrasib, Cetuximab May Benefit KRASG12c Colorectal Cancer Patients

Adagrasib, Cetuximab May Benefit KRASG12c Colorectal Cancer Patients
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

United-states , Texas , American , Redx-pharma , Daiichi-sankyo , Bristol-myers-squibb-medarex , Genentech-roche , Eli-lilly , Scott-kopetz , Navire-pharma , Astrazeneca-medimmune , Lutris-pharma

Adagrasib/Cetuximab Combo Has Activity in KRAS G12C+ Locally Advanced or mCRC

Adagrasib plus cetuximab elicited a 34% objective response rate in patients with previously treated KRAS G12C-mutant advanced colorectal cancer.

Texas , United-states , Houston , San-diego , California , American , Daiichi-sankyo , Bristol-meyers-squibb , Redx-pharma , Eli-lilly , Navire-pharma , Genentech-roche